A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558
NCT ID: NCT05685719
Last Updated: 2023-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
37 participants
INTERVENTIONAL
2023-01-04
2023-11-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1: TR
Subjects will take a single dose of test product 200mg/capsule on Day 1 of the study, then reference product 100mg/capsule on Day 8 of the study.
STI-1558
An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Part 1: RT
Subjects will take a single dose of reference product 100mg/capsule on Day 1 of the study, then test product 200mg/capsule on Day 8 of the study.
STI-1558
An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Part 1: Group 1
Subjects will take a single dose of STI-1558 200mg/capsule on Day 1. Starting from Day 4, subjects will orally take 200mg of itraconazole, q.d, for 6 consecutive days (Day 4 to Day 9). The 5th dose (Day 8) of itraconazole will be co-administered with STI-1558 (200 mg/capsule × 3 capsules) to subjects.
STI-1558
An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Itraconazole
A strong CYP3A4 inhibitor
Part 1: Group 2
Subjects will take a single dose of STI-1558 200mg/capsule on Day 1. Starting from Day 4, subjects will orally take 600mg of rifampin, q.d, for 9 consecutive days (Day 4 to Day 12). The 8th dose (Day 11) of rifampin will be co-administered with STI-1558 (200 mg/capsule × 3 capsules) to subjects.
STI-1558
An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Rifampin
A strong CYP3A4 inducer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
STI-1558
An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Itraconazole
A strong CYP3A4 inhibitor
Rifampin
A strong CYP3A4 inducer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy male and female subjects, aged 18 to 45 years (both inclusive).
3. Body mass index (BMI) is between 19 and 24 kg/m2 (both inclusive), and body weight of female subjects ≥ 45 kg, body weight of male subjects ≥ 50 kg.
4. Health status is good, the medical history, vital signs, physical examination, 12- lead ECG, laboratory tests (hematology, blood glucose, blood biochemistry, urinalysis, coagulation test), thyroid function (TSH, FT3, FT4) and serum virology test results are normal or abnormal with no clinical significance (NCS) during the screening period.
5. Female subjects of child-bearing potential must agree to use highly effective contraceptive methods from the screening period to 30 days after the last dose of the study drug, (See Appendix 2 Contraceptive Methods).
6. Male subjects considered fertile must agree to not plan to father a child, not donate sperm, and take effective contraceptive methods from the screening period to 30 days after the last dose of the study drug, (See Appendix 2 Contraceptive Methods).
7. Subjects who are able to communicate well with PI, as well as understand and adhere to the requirements of this study.
Exclusion Criteria
2. Known or suspected pregnancy, or breastfeeding.
3. Has a clinically relevant intolerance or allergy to drugs, or are known or suspected to have hypersensitivity to any ingredient in the STI-1558.
4. Only for Part 2: Known or suspected hypersensitivity to any ingredient in formulations of itraconazole and/or rifampicin (See the product label for the relevant information).
5. Has received an experimental agent (vaccine, drug, biologic, device, blood product or medication) within 1 month or 5 times half-life (whichever is longer) before the first dose of study drug.
6. Has a history of gastrointestinal (such as duodenal ulcer, alimentary tract hemorrhage, etc.), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs as determined by the Principal Investigator (PI, or designee).
7. Has a medical history of other significant diseases (including but not limited to respiratory, circulatory, digestive, hematological, endocrinological, immunological, dermatological, mental and nervous systems, facial diseases and other related diseases).
8. Has a major surgery within 3 months before the first dose of the study drug or plans to undergo surgery during the study.
9. Has a history of febrile illness within 14 days before the first dose of the study drug.
10. Has values above the 1.5 × upper limits of normal (ULN) at screening or Day -1 for the following laboratory measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST), and/or total bilirubin.
11. QTcF interval is prolonged at screening or Day -1 (male: QTcF interval ≥ 450 ms, female: QTcF interval ≥ 470 ms).
12. Vaccinated within 14 days before the first dose of the study drug or plans to be vaccinated during the study.
13. Use of BCRP substrates within 7 days before the first dose of the study drug (see Appendix 3).
14. Use of CYP3A4 strong inducers or inhibitors, or CYP1A2 strong inducers within 7 days before the first dose of the study drug (see Appendix 3).
15. Any marketed medication (prescription and nonprescription) within 14 days or 5 times the half-life (whichever is longer) before the first dose of study drug. (Excluding oral contraceptives, or topical ointments at the discretion of the PI (or designee)).
16. A known history of drug abuse within 2 years before the screening; or positive drug abuse test on Day -1.
17. Blood donation or blood loss of more than 400 mL within 3 months before the screening (excluding menstrual blood loss of women).
18. Weekly alcohol consumption of more than 14 units of alcohol (1 unit of alcohol = 360 mL of beer or 45 mL of spirit with the alcohol content of 40% or 150 mL of wine) in any week within the past 3 months before screening; or intake of alcohol- containing products within 48 hours before the first dose of the study drug, or cannot abstain from any alcohol product during the study, or positive breath alcohol test on Day -1.
19. Smoking history (≥ 5 cigarettes per day) within 3 months before the screening, or cannot abstain from any tobacco products during the study.
20. Excessive drinking of tea, coffee, or caffeine-containing beverage (at least 8 cups per day, 1 cup=250 mL) within 3 months before screening; intake of rich caffeine- or xanthine-containing food or drinks (e.g., coffee, tea, chocolate, cola drinks) within 48 hours before the first dose of the study drug.
21. Intake of food, juice, or drink containing grapefruit, lime, cinchona peel, or quinine within 48 h before the first dose of the study drug.
22. The results of serum virology test are positive or exceed the upper limit of the reference range, including: hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or treponema pallidum antibody (TP-Ab).
23. Subjects who are judged as not eligible to participate in this study by the PI (or designee).
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhejiang ACEA Pharmaceutical Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zhejiang Xiaoshan Hospital
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MPR-COV-102CN
Identifier Type: -
Identifier Source: org_study_id